ClinicalTrials.gg
RecruitingNCT06350097TROPION-Lung14Updated Aug 26, 2026

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 3 interventional study of Osimertinib and Datopotamab Deruxtecan in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Recruiting at 167 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
9th of 21
582 · median 278
Started
2024
with 3 others
Phase 3
9 of 21
3 open now
Primary completion
2028-03
later than 9 of 18 live
Registered
13th of 21
by date
Lead sponsor
11 of 21
AstraZeneca

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by planned enrollment, is one of 4 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 9 of the 18 other live ones, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC.

Study details include:

  1. The study duration will be event-driven, with an estimated duration of approximately 8 years.
  2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met.
  3. The visit frequency will be every 3 weeks during the treatment period.

Note: Participants on osimertinib treatment(osimertinib only arm or who have discontinued Dato-DXd while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression or IP discontinuation. Participants who are receiving osimertinib + Dato-DXd are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA.

Read the detailed description

This is a global Phase III, open-label, randomised, multicentre study assessing the efficacy and safety of osimertinib in combination with Datopotamab Deruxtecan compared with osimertinib in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC who have not received any prior therapy for advanced disease.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Non-small Cell Lung Cancer, NSCLC, Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Osimertinib, Dato-DXd, Datopotamab Deruxtecan, Tagrisso
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Participant must be ≥ 18 years.

    Type of Participant and Disease Characteristics

  2. or cytologically documented nonsquamous NSCLC. NSCLC of mixed histology is allowed if adenocarcinoma is the predominant histology. Mixed small-cell lung cancer and NSCLC histology, and sarcomatoid variant of NSCLC is ineligible.
  3. Stage IIIB or IIIC or Stage IV NSCLC or recurrent NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative surgery or definitive chemoradiation at the time of randomisation.
  4. Participants must not have received prior EGFR TKIs or other systemic therapy for Stage IIIB, IIIC or IV NSCLC.
  5. The tumour harbors at least 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other genomic alterations, which may include EGFR T790M, assessed by a CLIA-certified (US sites) or an accredited (outside of the US) local laboratory or by central prospective tissue testing.
  6. For participants enrolled in randomisation period, mandatory provision of an unstained, sample in a quantity sufficient to allow for central confirmation of the EGFR mutation status.
  7. of 0 or 1.
  8. At least one lesion not previously irradiated that qualifies as a 1.1 TL at baseline and can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with CT or MRI and is suitable for accurate repeated measurements.
  9. Adequate bone marrow reserve and organ function before the first dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including active bleeding diseases, history of allogenic organ transplant which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
  2. nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of osimertinib.
  3. History of another primary .
  4. Spinal cord compression and/or unstable .
  5. corneal disease.
  6. Has active or uncontrolled or C virus infection, as defined by Protocol.
  7. Past medical history of ILD/penumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require ), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  8. Has clinically severe pulmonary function compromise resulting from intercurrent pulmonary illnesses.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
582 participants (estimated)

Study arms

  • Experimental
    Arm 1: Osimertinib in combination with Datopotamab Deruxtecan

    Participants in this group will receive osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion q3w of Day 1 of every 21-day cycle.

    Drug: Osimertinib · Drug: Datopotamab Deruxtecan

  • Active comparator
    Arm 2: Osimertinib monotherapy

    Participants in this group will receive osimertinib 80 mg QD as oral tablet.

    Drug: Osimertinib

Interventions

  • Osimertinib 80 mg administered orally once daily (QD).

    Also known as: Osimertinib: Tagrisso, AZD9291

  • Datopotamab Deruxtecan 6 mg/kg administered as an intravenous (i.v.) infusion every 3 weeks (q3w).

    Also known as: Dato-DXd, DS-1062a

06

What researchers measure

Primary outcomes

  1. To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Progression Free Survival (PFS) by BICR in all randomised participants.

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression).

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.

Secondary outcomes

  1. To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Overall Survival (OS) in all randomised participants.

    OS defined as the time from randomisation until the date of death due to any cause.

    Time frame: It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.

  2. To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS on Central nervous system (CNS) metastases in participants with CNS metastases at baseline

    Central nervous system progression-free survival (CNS PFS) is defined as the time from randomisation until the date of objective CNS progression assessed by CNS BICR or death (by any cause in absence of CNS progression).

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.

  3. To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by investigator in all randomised participants.

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause (in the absence of progression).

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.

  4. To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Overall Response Rate (ORR) in all randomised participants with measurable disease at baseline.

    ORR is defined as the proportion of participants who have a confirmed Complete Response (CR) or confirmed Partial Response (PR), as determined by BICR (and investigator) per RECIST 1.1.

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.

  5. To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Duration of Response (DoR) in all randomised participants with measurable disease at baseline.

    DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR (and investigator) assessment or death due to any cause. The measure of interest is the median of DoR.

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.

  6. To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib on the prevention of CNS metastases

    Neuro-radiologist assessments according to CNS RECIST 1.1 to determine the presence/absence of CNS lesions at progression in participants without CNS metastases at baseline.

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.

  7. To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS2 in all randomised participants

    PFS2 will be defined as the time from randomisation to the earliest of the progression event (following the initial progression) subsequent to first subsequent anti-cancer therapy, or death.

    Time frame: It is anticipated that it will be analyzed by time of PFS primary which is about 3 years after the first participant has been randomised.

  8. To assess the Pharmacokinetics (PK) of osimertinib and Datopotamab Deruxtecan

    Concentration of osimertinib and its metabolite AZ5104, Datopotamab Deruxtecan, and DXd in plasma.

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant has been randomised.

  9. To investigate the immunogenicity of Datopotamab Deruxtecan

    Presence of ADAs for Datopotamab Deruxtecan (confirmatory results: positive or negative, titres, and neutralizing antibodies).

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant has been randomised, together with PFS primary.

  10. To compare the local EGFR mutation test result used for patient selection with the retrospective central cobas® EGFR Mutation Test v2 results from baseline tumour samples

    Concordance of EGFR mutation status between the local EGFR mutation test and the central cobas® EGFR Mutation Test v2 results from tumour samples with evaluable results.

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.

  11. To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan vs. osimertinib monotherapy based on the cobas® EGFR Mutation Test v2 plasma screening test result for Ex19del or L858R EGFR mutations

    PFS by Investigator by plasma EGFR mutation status PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause (in the absence of progression).

    Time frame: It is anticipated that it will be performed approximately 3 years after the first participant has been randomised, together with PFS primary.

07

Study locations

133 of 167 sites recruiting
  • Research Site
    Fountain Valley, California 92708, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Los Alamitos, California 90720, United States
    Recruiting
  • Research Site
    Los Angeles, California 90017, United States
    Recruiting
  • Research Site
    Los Angeles, California 90033, United States
    Recruiting
  • Research Site
    Orange, California 92868, United States
    Recruiting
  • Research Site
    San Diego, California 92123, United States
    Recruiting
  • Research Site
    Santa Monica, California 90404, United States
    Recruiting
  • Research Site
    Walnut Creek, California 94598, United States
    Recruiting
  • Research Site
    New Haven, Connecticut 06510, United States
    Recruiting
  • Research Site
    Washington D.C., District of Columbia 20037, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Jacksonville, Florida 32256, United States
    Recruiting
  • Research Site
    Ocala, Florida 34474, United States
    Recruiting
  • Research Site
    Orange City, Florida 32763, United States
    Recruiting
  • Research Site
    Honolulu, Hawaii 96819, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Chicago, Illinois 60611, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hinsdale, Illinois 60521, United States
    Recruiting
  • Research Site
    North Chicago, Illinois 60064, United States
    Recruiting
  • Research Site
    Fort Wayne, Indiana 46845, United States
    Recruiting
  • Research Site
    Bethesda, Maryland 20817, United States
    Recruiting
  • Research Site
    Detroit, Michigan 48201, United States
    Recruiting
  • Research Site
    Saint Paul, Minnesota 55102, United States
    Recruiting
  • Research Site
    Bridgeton, Missouri 63044, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Research Site
    Las Vegas, Nevada 89169, United States
    Recruiting
  • Research Site
    Brooklyn, New York 11212, United States
    Recruiting
  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Dallas, Texas 75390, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Houston, Texas 77090, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Webster, Texas 77598, United States
    Recruiting
  • Research Site
    Woodway, Texas 76712, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Fort Belvoir, Virginia 22060, United States
    Recruiting
  • Research Site
    Midlothian, Virginia 23114, United States
    Recruiting
  • Research Site
    Seattle, Washington 98104, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tacoma, Washington 98405, United States
    Recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • Research Site
    Camperdown, 2050, Australia
    Recruiting
  • Research Site
    Clayton, 3168, Australia
    Recruiting
  • Research Site
    Kogarah, 2217, Australia
    Recruiting
  • Research Site
    South Brisbane, 4101, Australia
    Recruiting
  • Research Site
    Westmead, 2145, Australia
    Recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Recruiting
  • Research Site
    Natal, 59075-740, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 91350-200, Brazil
    Recruiting
  • Research Site
    Salvador, 41253-190, Brazil
    Recruiting
  • Research Site
    São Paulo, 01246-000, Brazil
    Recruiting
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Research Site
    Beijing, 100029, China
    Recruiting
  • Research Site
    Beijing, 100034, China
    Recruiting
  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Changchun, 130000, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Chengdu, 610000, China
    Recruiting
  • Research Site
    Chengdu, 610042, China
    Recruiting
  • Research Site
    Chengdu, 610072, China
    Recruiting
  • Research Site
    Chongqing, 400030, China
    Recruiting
  • Research Site
    Chongqing, 402260, China
    Recruiting
  • Research Site
    Guangzhou, 510100, China
    Recruiting
  • Research Site
    Hangzhou, 310006, China
    Recruiting
  • Research Site
    Hangzhou, 31000, China
    Recruiting
  • Research Site
    Hangzhou, 310022, China
    Recruiting
  • Research Site
    Harbin, 150049, China
    Recruiting
  • Research Site
    Hefei, 230031, China
    Recruiting
  • Research Site
    Hefei, 230601, China
    Recruiting
  • Research Site
    Jinan, 250021, China
    Recruiting
  • Research Site
    Jinan, 250117, China
    Recruiting
  • Research Site
    Kunming, 650118, China
    Recruiting
  • Research Site
    Linhai, 317000, China
    Recruiting
  • Research Site
    Ningbo, 315010, China
    Recruiting
  • Research Site
    Shanghai, 200030, China
    Recruiting
  • Research Site
    Shanghai, 200433, China
    Recruiting
  • Research Site
    Shenyang, 110004, China
    Recruiting
  • Research Site
    Wenzhou, 325000, China
    Recruiting
  • Research Site
    Wuhan, 430022, China
    Recruiting
  • Research Site
    Wuhan, 430030, China
    Recruiting
  • Research Site
    Xi'an, 710061, China
    Recruiting
  • Research Site
    Xuzhou, 221000, China
    Recruiting
  • Research Site
    Yangzhou, 225001, China
    Recruiting
  • Research Site
    Zhengzhou, 450000, China
    Recruiting
  • Research Site
    Zhengzhou, 450008, China
    Recruiting
  • Research Site
    Angers, 49055, France
    Recruiting
  • Research Site
    Marseille, 13915, France
    Recruiting
  • Research Site
    Paris, 75005, France
    Recruiting
  • Research Site
    Strasbourg, 67091, Cedex, France
    Recruiting
  • Research Site
    Berlin, 13125, Germany
    Recruiting
  • Research Site
    Cologne, 51109, Germany
    Recruiting
  • Research Site
    Erfurt, 99089, Germany
    Recruiting
  • Research Site
    Frankfurt, 60488, Germany
    Recruiting
  • Research Site
    Göttingen, 37075, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Immenhausen, 34376, Germany
    Recruiting
  • Research Site
    Kiel, 24105, Germany
    Recruiting
  • Research Site
    Mainz, 55131, Germany
    Recruiting
  • Research Site
    München, 81925, Germany
    Recruiting
  • Research Site
    Hong Kong, 999077, Hong Kong
    Recruiting
  • Research Site
    Hong Kong, Hong Kong
    Recruiting
  • Research Site
    Jordan, 999077, Hong Kong
    Recruiting
  • Research Site
    Lai Chi Kok, Hong Kong
    Recruiting
  • Research Site
    Bangalore, 560027, India
    Recruiting

Showing the first 100 of 167 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lu S, Pulla MP, Mascarenhas E, Tanizaki J, Kim HR, Liu Y, Feng S, Zhang B, Toms L, Yang JC, Goldberg SB. TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer. Ther Adv Med Oncol. 2026 May 20;18:17588359261430561. doi: 10.1177/17588359261430561. eCollection 2026. PubMed 42182601 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2028, 46 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 46 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 5, 2024
StartActual
Apr 29, 2024
Primary completionEst.
Mar 21, 2028
CompletionEst.
Aug 29, 2031
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06350097
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
Apr 29, 2024
Primary completion
Mar 21, 2028 (estimated)
Completion
Aug 29, 2031 (estimated)
Last update
Aug 26, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion